- Home
- PEGA vs MIRM Comparison
PEGA vs MIRM Comparison
Compare PEGA & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEGA | MIRM |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.7B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PEGA | MIRM |
|---|---|---|
| Price | $31.24 | $122.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $60.13 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 2.3M | 945.6K |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | ★ 91.89 | 74.59 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $682,695,000.00 | $19,138,000.00 |
| Revenue This Year | $15.99 | $26.22 |
| Revenue Next Year | $11.90 | $22.04 |
| P/E Ratio | $178.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.66 | $50.25 |
| 52 Week High | $68.10 | $130.00 |
Technical Indicators
Market Signals| Indicator | PEGA | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 45.65 | 60.48 |
| Support Level | $28.66 | $88.92 |
| Resistance Level | $44.95 | N/A |
| Average True Range (ATR) | 1.36 | 6.48 |
| MACD | 0.34 | 0.71 |
| Stochastic Oscillator | 58.31 | 68.21 |
Price Performance
Historical ComparisonAbout PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.